GeoVax Labs achieves milestone in transition to validated manufacturing system

GeoVax Labs announced a significant milestone toward implementation of a validated chicken embryonic fibroblast based production system for the company’s MVA-based vaccines, with the release of its first lot of GEO-CM04S1 produced with a commercial manufacturing platform. This milestone marks the successful completion of the transfer and scale-up of manufacturing from the research-focused Center for Biomedicine & Genetics at City of Hope to the experienced CDMO ABL Europe, the Company’s cGMP manufacturing partner. David Dodd, GeoVax President and CEO, commented, “The successful establishment of cGMP production at ABL Europe represents great progress for GeoVax and the CM04S1 program. This latest manufacturing milestone also validates our choice of ABL Europe as our partner for cGMP production of our MVA-based vaccine candidates. This gives us a high degree of confidence in our manufacturing process as we move into late-stage clinical development for CM04S1, addressing a critically important unmet medical need for immunocompromised populations.”